The Middle East veterinary vaccine market is expected to reach approximately USD 678.3 million in 2025 and expand to around USD 1,053.3 million by 2035, reflecting a compound annual growth rate (CAGR) of 4.0% over the forecast period.
The Middle East veterinary vaccine market is expected to see steady and consistent growth during the years 2025 to 2035, particularly with increasing focus on animal health, food safety, and the prevention of zoonotic diseases. The livestock and poultry industries in the region are at the heart of domestic food supply as well as export economies; Vaccination is now a cost-saving option to reduce animal deaths, increase productivity, and control infectious outbreaks.
Governments' support will include national animal health plans to coordinate mass vaccination programs, enhance biosecurity, and upgrade veterinary services. The demand for vaccines will be for livestock (cattle, sheep, goats), poultry, aquaculture, and increasingly companion animals, as the urban population continues to embrace pet keeping.
Key Market Metrics
| Metric | Value (USD Million) |
|---|---|
| Industry Size (2025E) | USD678.3 Million |
| Industry Value (2035F) | USD 1,053.3 Million |
| CAGR (2025 to 2035) | 4.0% |
The Middle East market for veterinary vaccines has naturally shown development for the last ten years due to increased livestock production, a rising population of pet owners, and greater fear of zoonotic diseases. The past sense of the markets developed away from imported vaccines to a strategy of more local production, aided by government support and regional manufacturing. Important growth factors for the animal vaccines market included the rise of intensive farming, incidences of foot-and-mouth disease and avian flu, and regulatory interventions aimed at improving animal health standards.
International interest grew through collaborations, while local producers gained visibility with WHO and OIE standard vaccines. The cutting-edge technologies in immunization, like recombinant vaccine technologies, are presently trending in the market towards improved disease control and sustainability in animal health management in the region.
Explore FMI!
Book a free demo
The country is witnessing a booming growth in veterinary vaccine markets because of the flourishing equine industry, tremendous pet ownership, and an advanced veterinary health infrastructure in the UAE. Specialized vaccines are highly demanded in the country because the leadership role in endurance horse racing and breeding fuels the demand for such vaccines with respect to equine influenza and tetanus. Vaccination programs for livestock have been expanded to accommodate national food security goals and to ensure disease control through state-sponsored programs.
The UAE also boasts very stringent veterinary regulations and importation policies, both of which serve to raise the quality of vaccines. Increased pet ownership, above all in Dubai and Abu Dhabi, has also driven up the demand for companion animal vaccines. Increased partnerships with international vaccine manufacturers and growing investment in biotech solutions have created a dynamic in the country's market concerning veterinary vaccines.
Saudi Arabia's rapidly developing and flourishing market for veterinary vaccines is built on the sheer volume of livestock and a hugely spread government initiative to combat animal diseases. Among the possible future investment areas under the Kingdom's Vision 2030 strategy, agricultural growth and food security should mean an increase in investment in livestock vaccination.
High-end horse racing events such as the Saudi Cup underpin the equine vaccine market, while increasing numbers of pet owners in cities mean a growing demand for vaccines for companion animals. The disease control strategies of the government include national vaccination programs against foot-and-mouth disease and brucellosis, which add to the market expansion: availability through international collaboration supplemented by private sector investment.
Turkey's veterinary vaccine market is developing vigorously under such a robust and mature livestock sector and a vigorous equine racing industry with government-supported vaccination programs. There is also a huge agricultural base that's a bit older, which means there is a need for wide coverage and quite extensive field vaccination campaigns to keep things like brucellosis and lumpy skin disease under control.
The demand for sophisticated vaccines against common ailments in equines feeds a competitive horse racing industry regulated by the Jockey Club of Turkey. Increasing urbanization and population, such as those in Istanbul and Ankara, result in an increased percentage of pet ownership, fostering a boom in companion animal vaccines.
The government is working to strengthen local vaccine production, which they manufacture in conjunction with growing partners in global biotech firms. This promises to expand the market and ensure increased accessibility to vaccines in the coming years.
A Lack of Trained Veterinarians Impacts the Effective Administration of Vaccines and Disease Management Programs.
The various challenges being faced by the Middle East veterinary vaccine industry are structural and operational. Various regulatory environments for different countries prevent vaccines from being timely approved and harmonized, limiting their cross-border distribution and trade. Other focused issues include poor standards in cold chain logistics, which affect vaccine stability and efficacy, particularly in remote or rural situations. Many areas also have shortages of trained veterinary professionals, which also affects vaccine administration and monitoring.
Even with government and donor efforts, vaccines remain unaffordable to most in low-income and conflict-affected areas. On top of that, smallholder farmers sometimes hesitate to vaccinate animals due to a lack of knowledge about the vaccines, perceived costs, or mistrust of government programs. In addition, it limits tracking and response capabilities in real time because of the absence of consolidated animal disease surveillance networks.
Expansion of Veterinary Clinics in Major Cities Strengthens the Availability of Vaccines and Advanced Veterinary Treatment Options.
Though there are challenges, the Middle East veterinary vaccine market is creating many opportunities that can quicken growth in this area. The growing trend of regional manufacturing of vaccines, particularly in the Gulf Cooperation Council (GCC), as governments look at pharmaceutical sovereignty by reducing dependency on imports, is a critical opportunity through which they can bring down prices, accelerate distribution, and improve response during outbreaks.
Urbanization, as well as rising disposable income, is a growing niche for pet ownership that is demanding increasing scopes of companion animal mammalian vaccines for diseases such as rabies and canine distemper. Further, awareness of zoonotic diseases has increased post-COVID-19, which has galvanized support for One Health initiatives combining human, animal, and environmental health strategies.
Such frameworks would provide suitable platforms upon which to expand veterinary vaccination programs and gather multi-sectoral funding. The increasing embrace of digital health tools, one such example being mobile-based applications for livestock management and vaccination reminder enhancement, is promoting better adherence and farmer engagement.
Poultry Vaccine Demand
The poultry sector represents the most dynamic component of the veterinary vaccine market in the Middle East. Poultry meat and eggs form a significant part of the regional diet, and countries such as Saudi Arabia, Egypt, and Iran are among the largest producers in the region. Diseases like Newcastle disease, infectious bronchitis, avian influenza, and Marek’s disease are endemic threats that prompt consistent vaccination protocols.
Layer and broiler farms, particularly in the GCC, operate on intensive farming models that rely on strict biosecurity and scheduled immunization. The rise of vertically integrated poultry businesses has improved compliance with best practices and facilitated the adoption of thermostable and multivalent vaccines. Moreover, demand is shifting toward recombinant and vector-based poultry vaccines that offer improved protection and administration convenience.
Emerging Zoonotic Threats
The presence of zoonotic diseases like the Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Rift Valley fever, and brucellosis has made the case for considerable veterinary vaccination systems across the Middle East more imminent. The underlying diseases interfere with livestock productivity and also possess direct public health threats to some measure, and hence they have an area of concern globally.
One Health is a paradigm that recognizes the interrelationship among human health, animal health, and environmental health, and this has become a unifying science behind vaccine-oriented surveillance and control programs. Hence, governments are now including veterinary immunization within the frameworks of epidemic preparedness plans. For instance, vaccine campaigns for Rift Valley fever are being coordinated with vector control and restrictions on livestock movements.
As the rising needs of livestock products, growing awareness for the health of animals, and governmental initiatives for improvement of veterinary healthcare structure have matured well to trigger a steady growth for the veterinary vaccine industry in Middle East countries between 2020 to 2024, which is approximately valued at USD 652.2 million in 2024 and projected to exceed USD 1,053.3 million by 2035, it translates to a compound-anonal growth rate (CAGR) of about 4% for the forecast period.
The key factors propelling this growth include region-specific vaccines for diseases targeting camels and collaborative programs for disease control in line with regional standards.
| Market Aspect | 2020 to 2024 |
|---|---|
| Regulatory Landscape | The application of regulations guaranteeing the safety and effectiveness of veterinary vaccines results in uniform procedures and usage standards. |
| Technological Advancements | Introduction of new vaccines with better formulations and delivery systems, increasing immunogenicity, and ease of administration. |
| Consumer Demand | Increased recognition and appreciation of veterinary vaccines by animal producers and pet owners are creating increased demand for preventive healthcare options. |
| Market Growth Drivers | Increases in zoonotic disease prevalence, improvements in vaccine technology, and a move toward preventive care within veterinary clinics. |
| Sustainability | Early initiatives in environmentally friendly manufacturing processes and vaccine development with lower environmental footprints. |
| Supply Chain Dynamics | Reliance on specialist suppliers for high-quality raw materials, with localization of production aimed at lessening supply chain risks seen through major global events. |
| Market Aspect | 2025 to 2035 |
|---|---|
| Regulatory Landscape | Ongoing monitoring and possible refinement of regulations to reconcile animal health with technological progress, coupled with accelerated approval procedures for new vaccines targeting new diseases. |
| Technological Advancements | New-generation vaccines involving biotechnology, including recombinant DNA technology, increasing efficacy and allowing targeting of a wider range of pathogens. |
| Consumer Demand | Increased use of total animal health programs due to improved vaccines and preventive medicine emphasis, causing broad application to a variety of animal species. |
| Market Growth Drivers | Increases in the population of livestock animals and companion animals, growing veterinary healthcare infrastructure investment, ongoing advancements in technology supporting vaccine effectiveness, and global pressure on food safety and public health. |
| Sustainability | Implementation of sustainable methods in vaccine production and delivery, such as the utilization of recyclable materials and energy-efficient production processes, according to international environmental standards, lowers the carbon footprint of veterinary vaccines. |
| Supply Chain Dynamics | Enhancing domestic manufacturing capacities through technological improvement and strategic collaborations, resulting in minimized reliance on imports, enhanced supply chain strength, and quick responses to arising animal health requirements. |
Market Outlook
The Veterinary Vaccines market in the UAE is primarily driven by the strong horse racing culture and elite endurance riding events that the country has to offer in addition to robust government support for sport. The country is known for maximum investments in sophisticated equine medical care, owning expensive stables, hiring specialized veterinary hospitals, etc., focusing on the best treatments.
This increased activity, in conjunction with international equestrian events such as the Dubai World Cup, drives the demand for regenerative medicine, joint health solutions and performance-enhancing therapeutics. Rich owners propel the adoption of advanced diagnostics, biologics, and preventative care, rendering the UAE a premium market for equine therapeutics.
Factors Driving Market Growth
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 5.1% |
Market Outlook
Royal patronage, high-volume investments in equestrian sports, and a budding breeding industry characterize the Saudi Arabian Veterinary Vaccines market, which is poised for accelerated growth. The Kingdom is home to prominent horse racing and show-jumping events such as the Saudi Cup, which has helped grow the demand for lameness treatments, regenerative therapies and specialty veterinary care.
An expansion in veterinary infrastructure, government support for equine welfare, and an increasing number of private equestrian centers drive sustained growth in the market. Well, good quality equine healthcare services, such as the adoption of biologics, NSAIDs, and advanced diagnostic tools, continue to be key contributors to services.
Factors Driving Market Growth
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 4.9% |
Market Outlook
Türkiye’s Developing Veterinary Vaccines Market-Horse Racing Industry, Equestrian Culture, and Government-Supported Breeding Programs. The country’s expansive racing sector, spearheaded by the Jockey Club of Turkey, also drives demand for joint health solutions, anti-inflammatory drugs and lameness therapies.
Improvements in diagnostics, surgical techniques, and regenerative medicine are also enhancing treatment outcomes. Increasing horse ownership, as well as a significant rise in recreational riding trends, are further fueling growth in the market, along with growing investments in developing effective equine health solutions.
Factors Driving Market Growth
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 3.8% |
Market Outlook
Jordan’s Veterinary Vaccines market is profiting from a longstanding Arabian horse breeding tradition and growing equestrian tourism, and it is underpinned by support from royalty for the industry. Regional events for endurance riding and show-jumping are also held in the country, creating a need for joint care, pain management and preventive healthcare.
Investment in veterinarian education, specialty clinics, and equine welfare initiatives are helping to increase access to advanced treatments. Rising demands for biologics, NSAIDs and vaccines are driven by greater awareness of equine health management.
Factors Driving Market Growth
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 3.7% |
Market Outlook
The Sudan Veterinary Vaccines market is stimulated by the role of horses in agriculture, transport and traditional sports, but not racing or recreation. The high demand for vaccines, antiparasitic treatments, and anti-inflammatory drugs is attributed to the widespread prevalence of infectious diseases and harsh climatic conditions.
Challenges include limited access to specialized equine health-care infrastructure and veterinary expertise, but international aid and veterinary training programs are enhancing the market. Ongoing efforts to improve disease control and preventive care are slowly strengthening the nation’s equine health infrastructure.
Factors Driving Market Growth
Market Forecast
| Year | CAGR (2025 to 2035) |
|---|---|
| 2025 to 2035 | 2.7% |
The Attenuated Live Vaccines Segment Dominates the Market Due to Their Ability to Induce Long-Lasting Immunity.
The vaccines that are widely available in the Middle East veterinarian's pharmacy have strong immunogenicity and long-lasting immunity, especially in livestock and poultry farming; hence, they have become widely accepted. Viral diseases such as Newcastle disease, foot-and-mouth disease, and peste des petits ruminants are the diseases that these vaccines contend against.
The high prevalence of endemic diseases, the government's institution of mass immunization campaigns, and the growing livestock trade across the GCC and Levant regions have been the primary driving forces for this segment. Saudi Arabia, Egypt, and Jordan are the main leaders in deploying live vaccines in these contexts with public-private partnerships. Future developments include thermostable vaccine formulations, intranasal delivery systems for ruminants, and regional manufacturing hubs for strategic stockpiling.
The Inactivated Vaccines Segment Dominates The Market Due To Their Superior Safety Profile.
Inactivated vaccines are increasingly becoming popular investments in the Middle East given their safety profile, regulatory acceptability, and applicability for disease-free zones. It is largely used in poultry, bovine, and equine sectors, especially against Avian Influenza, Rabies, and Brucellosis.
The growth of commercial poultry farming, livestock production geared towards exports, and the regulatory changes leaning towards biosecure vaccine technologies have contributed to the benefits brought about by these vaccines. UAE and Oman are building a cold chain infrastructure for extended usage in the future. This future innovation includes adjuvanted inactivated vaccines for greater response, oil-emulsion vaccines for avian species, and multi-valent formulations aimed to be pathogen-specific in different regions.
The Livestock Animals Segment Dominates the Market Due to The Middle East’s Heavy Reliance On Animal Husbandry.
Livestock accounts for the highest market share among the different animal segments, thereby contributing toward ensuring food security and economic growth within the Middle East. Government-sponsored disease control initiatives against FMD, PPR, and Newcastle disease fuel high demand for vaccines against cattle, sheep, goats, and poultry. Outbreaks of zoonotic diseases such as Rift Valley Fever and Brucellosis are additional causes for extensive vaccination.
Furthermore, the market is also seeing enough investment in modern livestock farming, disease surveillance programs, and veterinary healthcare infrastructure. Demand has also been supported by an expansion of large-scale poultry farms and ruminant production in Saudi Arabia, the UAE, and Egypt. Government subsidies and collaborative arrangements with vaccine manufacturers also support adoption rates.
The Companion Animals Segment Dominates the Market Due to The Rising Pet Adoption Rates in the Middle East.
The rising pet adoption, coupled with an increasing awareness towards pet health, along with rising disposable income in the region, is likely to boost the companion animal segment within the Middle East veterinary vaccine market. Increased demand for canine and feline vaccines, especially rabies, parvovirus, distemper, and feline calicivirus, is likely attributed to the compulsion of vaccination by countries such as the UAE and Saudi Arabia.
Additionally, equine vaccines for West Nile virus and equine influenza are in demand, especially in regions with a strong horse racing and breeding culture. Veterinary clinics and pet healthcare facilities are growing, supported by government initiatives promoting responsible pet ownership. The rise of pet insurance, advanced veterinary
The Middle East veterinary vaccine market is rapidly progressing due to the growing concern about animal health, investments to enhance production in livestock, and initiatives undertaken by governments to control zoonotic diseases. There is an increase in demand for vaccines among companion animals and livestock for the prevention of foot and mouth disease, avian influenza, rabies and infectious diseases.
Key players in the market, alongside multinational animal health companies currently ramping up their regional presence through strategic alliances, acquisitions, and launches of novel vaccines, are serious contenders entrenching local producers on the ground with government support in terms of subsidies, research grants, and regulatory assistance to boost domestic production capacity.
Market Share Analysis by Company
| Company Name | Estimated Market Share (%) |
|---|---|
| Zoetis Inc. | 24-28% |
| Merck Animal Health | 20-24% |
| Boehringer Ingelheim | 14-18% |
| Ceva Santé Animale | 10-14% |
| Jordan Bio-Industries Center (JOVAC) | 5-9% |
| Other Companies (combined) | 20-30% |
| Company Name | Key Offerings/Activities |
|---|---|
| Zoetis Inc. | Offers a broad range of vaccines for livestock and companion animals, with a focus on poultry and cattle vaccines in the region. |
| Merck Animal Health | Provides vaccines for FMD, rabies, and respiratory diseases, and partners with regional distributors for expanded reach. |
| Boehringer Ingelheim | Supplies viral and bacterial vaccines, particularly for poultry and ruminants, with regional offices and vet education initiatives. |
| Ceva Santé Animale | Specializes in poultry and swine vaccines, with strong distribution partnerships in the Gulf Cooperation Council (GCC) countries. |
| JOVAC | Local manufacturer offering vaccines tailored for endemic diseases, including PPR, Newcastle, and Rift Valley Fever. |
Key Company Insights
Zoetis Inc. (24-28%)
The Middle East veterinary vaccine market is dominated by Zoetis Inc. which has a comprehensive portfolio of products spanning livestock and companion animals. With strong distribution networks, partnerships and localized supply chains, the company manages its vaccine supply and availability effectively. It further nurtures its position in the market through research-based development and partnerships with local authorities.
Merck Animal Health (20-24%)
Merck Animal Health is essential for immunizing livestock, and the company applies its global expertise to address regional epidemics. It invests in government and research partnerships that guarantee a supply of vaccines for diseases such as foot-and-mouth disease and avian influenza. THE SELECTOR's regional domination is cemented through its focus on immunization programs, educational initiatives, and customized veterinary solutions.
Boehringer Ingelheim (14-18%)
Boehringer Ingelheim is deep in the poultry and ruminant health sector, bringing innovative vaccines and veterinary support expertise. By offering disease prevention strategies, biosecurity programs, and diagnostic solutions, the company built credibility both with farmers and veterinarians. Its focus on innovation and ongoing product development leads to sustainable market growth in the Middle East.
Ceva Santé Animale (10-14%)
Ceva Santé Animale plays a significant role in avian health with its tailored vaccine solutions and regional disease monitoring. Targeted vaccines for poultry farming and livestock constitute another major investment in research by the company. Ceva stays relevant through improved production productivity and maintaining local farms for partnership.
JOVAC (5-9%)
JOVAC is a prominent regional vaccine producer committed to creating WHO- and OIE-compliant vaccines suitable for Middle Eastern climates. The company makes an essential contribution to the fight against endemic diseases through localized research and affordable solutions. Through its partnership with veterinary institutions and government programs, it contributes to regional disease eradication efforts and vaccine accessibility.
Other Key Players (20-30% Combined)
Additional companies supporting the Middle East veterinary vaccine market include:
These firms contribute to disease prevention efforts in livestock and poultry through cost-effective vaccine solutions, knowledge-sharing with local governments, and regional distribution partnerships.
The Middle East Veterinary Vaccine industry is projected to witness CAGR of 4.0% between 2025 and 2035.
The Middle East Veterinary Vaccine industry stood at USD 652.2 million in 2024.
The Middle East Veterinary Vaccine industry is anticipated to reach USD 1,053.3 million by 2035 end.
China is expected to show a CAGR of 4.9% in the assessment period.
The key players operating in the Middle East Veterinary Vaccine industry are Zoetis Inc., Merck Animal Health, Boehringer Ingelheim, Ceva Santé Animale, Jordan Bio-Industries Center (JOVAC), Vaxxinova, Biovet JSC, Indian Immunologicals Ltd., Elanco Animal Health, HIPRA and Others.
Attenuated Live Vaccines, Inactivated Vaccines, Toxoid Vaccines, DNA Vaccines, Recombinant Vaccines and Others.
Companion Animals, Livestock Animals and Equine.
Foot and Mouth Disease, Newcastle Disease, PPRS, Canine Parvovirus, Brucellosis, Avian Influenza and Others.
Hospital Pharmacies, Veterinary Clinics, Private Veterinary Pharmacies and Others.
United Arab Emirates, Saudi Arabia, Türkiye, Jordan, Sudan, Egypt and Rest of Middle East.
The Prurigo Nodularis (PN) Treatment Market is segmented by product, and end user from 2025 to 2035
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market Analysis by Drug Class, Distribution Channel, and Region through 2035
Atrophic Vaginitis Treatment Market Analysis And Forecast by Diagnosis, Treatment, Therapy Type, Distribution Channel, and Region through 2035
Adrenal Crisis Management Market Analysis and Forecast, By Diagnosis Method, Treatment Method, Distribution Channel, and Region, through 2035
Birch Allergy Treatment Market Analysis by Drug Class, Route of Administration, Distribution Channel and Region: Forecast from 2025 to 2035
Cancer Vaccines Market Analysis by Technology, Treatment Method, Application and Region from 2025 to 2035
Middle East Veterinary Vaccines Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
